Welcome to our dedicated page for Renovorx news (Ticker: RNXT), a resource for investors and traders seeking the latest updates and insights on Renovorx stock.
Renovorx Inc (RNXT) pioneers targeted therapeutic delivery systems designed to transform cancer treatment and vascular interventions through its proprietary Trans-Arterial Micro-Perfusion technology. This page serves as the definitive source for verified updates about the clinical-stage innovator’s progress in precision medicine.
Investors and medical professionals will find comprehensive coverage of FDA clearances, clinical trial milestones, and strategic partnerships. Track developments in RNXT’s pipeline including oncology-focused device innovations and evidence-based research validating its Renovocath™ delivery platform.
Key updates include regulatory submissions, peer-reviewed study results, manufacturing collaborations, and financial performance reports. All content is curated to support informed analysis of RNXT’s position in the competitive medical device sector while adhering to strict journalistic standards.
Bookmark this page for streamlined access to essential RNXT developments. Combine our real-time updates with Stock Titan’s financial tools to monitor this innovator in localized therapeutic delivery systems.
RenovoRx, a biopharmaceutical company focused on targeted drug delivery for locally advanced pancreatic cancer, announced the appointment of Dr. Robert J. Spiegel to its Board of Directors as of April 25, 2023. With over 40 years in the biopharmaceutical sector, Dr. Spiegel has been instrumental in more than 30 FDA drug approvals, including significant cancer therapies. His leadership is expected to drive discussions with the FDA to expedite progress with RenovoGem™, currently in a Phase III trial for LAPC. RenovoRx's innovative drug delivery platform, RenovoTAMP™, aims to improve treatment outcomes while minimizing side effects. The company holds multiple patents and has received Orphan Drug Designation for its therapies. CEO Shaun Bagai emphasized ongoing trial enrollment and regulatory engagement as part of the company’s growth strategy.
RenovoRx, a biopharmaceutical company, presented interim data from its Phase III TIGeR-PaC study at the AACR Annual Meeting. The analysis revealed that patients receiving the RenovoGem therapy for locally advanced pancreatic cancer exhibited a 60% improvement in median overall survival, reaching 16 months compared to 10 months for those on standard chemotherapy (IV gemcitabine and nab-paclitaxel). Additionally, RenovoGem patients experienced over a 65% reduction in adverse events such as nausea and fatigue. The Data Monitoring Committee found the results promising enough to continue the trial, which aims to enroll 114 patients. CEO Shaun Bagai emphasized the therapy's potential to change treatment protocols and enhance patient life quality. The next interim analysis is anticipated in mid to late 2024.
FAQ
What is the current stock price of Renovorx (RNXT)?
What is the market cap of Renovorx (RNXT)?
